Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOxatomide
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Oxatomide
- Accession Number
- DB12877
- Type
- Small Molecule
- Groups
- Investigational
- Description
Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
- Structure
Structure for DB12877 (Oxatomide)
- Synonyms
- Not Available
- Categories
- UNII
- J31IL9Z2EE
- CAS number
- 60607-34-3
- Weight
- Average: 426.564
Monoisotopic: 426.241961602 - Chemical Formula
- C27H30N4O
- InChI Key
- BAINIUMDFURPJM-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
- IUPAC Name
- 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
- SMILES
- OC1=NC2=CC=CC=C2N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
Pathway Category Oxatomide H1-Antihistamine Action Drug action Oxatomide H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Oxatomide. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Oxatomide. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Oxatomide. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Oxatomide. Experimental, Illicit Amphetamine Amphetamine may decrease the sedative activities of Oxatomide. Approved, Illicit, Investigational Benzphetamine Benzphetamine may decrease the sedative activities of Oxatomide. Approved, Illicit Benzylpenicilloyl Polylysine Oxatomide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Oxatomide. Approved, Investigational Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Oxatomide. Approved Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Oxatomide. Approved Chlorphenamine The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Oxatomide. Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Oxatomide. Illicit, Withdrawn Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Oxatomide. Approved, Investigational Clemastine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Clemastine. Approved, Investigational Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxatomide. Approved Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Oxatomide. Approved, Illicit Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Oxatomide. Approved, Illicit Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Oxatomide. Approved Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Oxatomide. Approved, Investigational Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Oxatomide. Approved, Vet Approved Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxatomide. Approved Fluoxetine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Fluoxetine. Approved, Vet Approved Gepefrine Gepefrine may decrease the sedative activities of Oxatomide. Experimental Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Oxatomide. Approved, Investigational Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Oxatomide. Approved Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Oxatomide. Approved Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Oxatomide. Approved, Investigational Loratadine The risk or severity of QTc prolongation can be increased when Loratadine is combined with Oxatomide. Approved, Investigational Mephedrone Mephedrone may decrease the sedative activities of Oxatomide. Investigational Mephentermine Mephentermine may decrease the sedative activities of Oxatomide. Approved Methamphetamine Methamphetamine may decrease the sedative activities of Oxatomide. Approved, Illicit Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Oxatomide. Experimental Midomafetamine Midomafetamine may decrease the sedative activities of Oxatomide. Experimental, Illicit, Investigational MMDA MMDA may decrease the sedative activities of Oxatomide. Experimental, Illicit Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxatomide. Approved Phentermine Phentermine may decrease the sedative activities of Oxatomide. Approved, Illicit Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Oxatomide. Approved Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Oxatomide. Approved Quetiapine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Quetiapine. Approved Ritobegron Ritobegron may decrease the sedative activities of Oxatomide. Investigational Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxatomide. Approved, Vet Approved Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxatomide. Approved Valproic Acid The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Oxatomide. Approved - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240225
- PubChem Compound
- 4615
- PubChem Substance
- 347829033
- ChemSpider
- 4454
- BindingDB
- 76863
- ChEBI
- 31943
- ChEMBL
- CHEMBL13828
- PharmGKB
- PA163522137
- Wikipedia
- Oxatomide
- ATC Codes
- R06AE06 — Oxatomide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Muscular Dystrophy, Duchenne 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0393 mg/mL ALOGPS logP 4.71 ALOGPS logP 4.62 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 12.92 ChemAxon pKa (Strongest Basic) 8.01 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 38.82 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 130.94 m3·mol-1 ChemAxon Polarizability 48.56 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzimidazoles / N-alkylpiperazines / Aralkylamines / N-substituted imidazoles / Heteroaromatic compounds / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 2 more
- Substituents
- Diphenylmethane / Benzimidazole / N-alkylpiperazine / Aralkylamine / 1,4-diazinane / N-substituted imidazole / Piperazine / Azole / Imidazole / Heteroaromatic compound show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 18:57 / Updated on August 02, 2018 06:44